148 related articles for article (PubMed ID: 18163518)
1. The effects of rituximab on immunocompetency in patients with autoimmune disease.
Looney RJ; Srinivasan R; Calabrese LH
Arthritis Rheum; 2008 Jan; 58(1):5-14. PubMed ID: 18163518
[No Abstract] [Full Text] [Related]
2. Rituximab treatment in children: comment on the review by Looney et al.
Bader-Meunier B
Arthritis Rheum; 2008 Aug; 58(8):2583; author reply 2583-4. PubMed ID: 18668567
[No Abstract] [Full Text] [Related]
3. mAbs in nonlupus autoimmune rheumatic disease.
Whelan BR; Isenberg DA
Curr Opin Hematol; 2009 Jul; 16(4):280-4. PubMed ID: 19444098
[TBL] [Abstract][Full Text] [Related]
4. A review of the current use of rituximab in autoimmune diseases.
Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
[TBL] [Abstract][Full Text] [Related]
5. Targeted ITP strategies: do they elucidate the biology of ITP and related disorders?
Bennett CM; de Jong JL; Neufeld EJ
Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):706-9. PubMed ID: 16933263
[TBL] [Abstract][Full Text] [Related]
6. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab.
Fleischmann RM
Semin Arthritis Rheum; 2009 Feb; 38(4):265-80. PubMed ID: 18336874
[TBL] [Abstract][Full Text] [Related]
7. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
Guzman Moreno R
Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
[TBL] [Abstract][Full Text] [Related]
8. A case of Evans syndrome combined with systemic lupus erythematosus successfully treated with rituximab.
Kittaka K; Dobashi H; Baba N; Iseki K; Kameda T; Susaki K; Kitanaka A; Kubota Y; Ishida T
Scand J Rheumatol; 2008; 37(5):390-3. PubMed ID: 18609263
[TBL] [Abstract][Full Text] [Related]
9. Expanding possibilities in the treatment of patient groups with previously difficult-to-treat patients.
Dörner T; Burmester GR
Curr Opin Rheumatol; 2010 May; 22(3):235-6. PubMed ID: 20351494
[No Abstract] [Full Text] [Related]
10. Biotechnological drugs: the breakthrough in autoimmune rheumatic conditions.
Cavagna L; Saketkoo LA; Schwarting A; Caporali R
Biomed Res Int; 2014; 2014():481973. PubMed ID: 25180183
[No Abstract] [Full Text] [Related]
11. Rituximab in autoimmune pancytopenia: a case report and review of literature.
Reale LD; Besa EC
Ann Hematol; 2007 Dec; 86(12):913-6. PubMed ID: 17541587
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of rituximab in refractory cold agglutinin disease.
Panwar U; Mathews C; Cullis JO
Int J Lab Hematol; 2008 Aug; 30(4):331-3. PubMed ID: 18665831
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment with rituximab of autoimmune haemolytic anaemia causing dialysis-dependent acute renal failure.
Brown CE; Traynor JP; Sharp RA; Fox JG
Nephrol Dial Transplant; 2007 Sep; 22(9):2730-1. PubMed ID: 17575312
[No Abstract] [Full Text] [Related]
14. Monozygotic twins with stiff person syndrome and autoimmune thyroiditis: rituximab inefficacy in a double-blind, randomised, placebo controlled crossover study.
Venhoff N; Rizzi M; Salzer U; Bossaller L; Thoden J; Eibel H; Walker UA
Ann Rheum Dis; 2009 Sep; 68(9):1506-8. PubMed ID: 19674986
[No Abstract] [Full Text] [Related]
15. Monoclonal antibodies in the immunotherapy of autoimmune diseases.
Perosa F; Luccarelli G; Prete M; Dammacco F
Ann Ital Med Int; 2001; 16(4):220-32. PubMed ID: 11799630
[TBL] [Abstract][Full Text] [Related]
16. Ocrelizumab: a step forward in the evolution of B-cell therapy.
Kausar F; Mustafa K; Sweis G; Sawaqed R; Alawneh K; Salloum R; Badaracco M; Niewold TB; Sweiss NJ
Expert Opin Biol Ther; 2009 Jul; 9(7):889-95. PubMed ID: 19463076
[TBL] [Abstract][Full Text] [Related]
17. Occurrence of cold agglutinin disease in RA patient during etanercept therapy successfully treated with rituximab.
Malesci D; La Montagna G
Rheumatology (Oxford); 2008 May; 47(5):734-5. PubMed ID: 18326535
[No Abstract] [Full Text] [Related]
18. Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy.
Zeni P; Finger E; Scheinberg MA
Ann Rheum Dis; 2008 Jul; 67(7):1055-6. PubMed ID: 18556452
[No Abstract] [Full Text] [Related]
19. A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis.
van den Bemt BJ; Vos K; den Broeder AA; Blom M; Thurlings RM; Bartelds GM; Stapel SO; Barrera P; Tak PP; Nurmohamed MT; Wolbink GJ
Ann Rheum Dis; 2009 Aug; 68(8):1368-9. PubMed ID: 19605744
[No Abstract] [Full Text] [Related]
20. Therapeutic use of Rituximab for sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease).
Pagel JM; Lionberger J; Gopal AK; Sabath DE; Loeb K
Am J Hematol; 2007 Dec; 82(12):1121-2. PubMed ID: 17696200
[No Abstract] [Full Text] [Related]
[Next] [New Search]
